Apollo Therapeutics is a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines
The Series C financing was led by Patient Square Capital. (Credit: 金 运 on Unsplash)
Apollo Therapeutics, a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, today announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5m and bringing the total raised in this round by the Company during 2023 to $260m.
“We are delighted to have completed the second close of our Series C financing in December and thank existing investors for their additional support, as well as welcoming new shareholders to the Company,” said Dr. Richard Mason, Chief Executive Officer of Apollo Therapeutics. “We are progressing a broad and diversified pipeline of over 20 uncorrelated therapeutic programs, with multiple assets about to enter the clinic in early 2024. We look forward to an exciting year ahead.”
The Series C financing was led by Patient Square Capital and included participation by multiple new investors including M&G plc and two of the largest US public pension plans, along with existing investors including Rock Springs Capital.
Proceeds from the Series C fundraise are being used to (i) advance pipeline programs through clinical development and further fund Apollo’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, (ii) license or acquire additional clinical stage programs that meet strict selection criteria.
Source: Company Press Release